Thomas U Ahearn1, Nairi Tchrakian1, Kathryn M Wilson1, Rosina Lis1, Elizabeth Nuttall1, Howard D Sesso1, Massimo Loda1, Edward Giovannucci1, Lorelei A Mucci1, Stephen Finn1, Irene M Shui1. 1. Departments of Epidemiology (T.U.A., K.M.W., E.N., H.D.S., E.G., L.A.M., I.M.S.) and Department of Nutrition (E.G.), Harvard T. H. Chan School of Public Health, Department of Medical Oncology (R.L., M.L.), Dana-Farber Cancer Institute, Divisions of Preventive Medicine (H.D.S.), and Channing Division of Network Medicine (K.M.W., E.G., L.A.M.), Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115; Department of Histopathology Research (N.T., S.F.), Trinity College, Dublin 8, Ireland; and Public Health Sciences Division (I.M.S.), Fred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Abstract
CONTEXT: Prostate cancer metastases preferentially target bone, and the calcium-sensing receptor (CaSR) may play a role in promoting this metastatic progression. OBJECTIVE: We evaluated the association of prostate tumor CaSR expression with lethal prostate cancer. DESIGN: A validated CaSR immunohistochemistry assay was performed on tumor tissue microarrays. Vitamin D receptor (VDR) expression and phosphatase and tensin homolog tumor status were previously assessed in a subset of cases by immunohistochemistry. Cox proportional hazards models adjusting for age and body mass index at diagnosis, Gleason grade, and pathological tumor node metastasis stage were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of CaSR expression with lethal prostate cancer. SETTING: The investigation was conducted in the Health Professionals Follow-up Study and Physicians' Health Study. PARTICIPANTS: We studied 1241 incident prostate cancer cases diagnosed between 1983 and 2009. MAIN OUTCOME: Participants were followed up or cancer-specific mortality or development of metastatic disease. RESULTS: On average, men were followed up 13.6 years, during which there were 83 lethal events. High CaSR expression was associated with lethal prostate cancer independent of clinical and pathological variables (HR 2.0; 95% CI 1.2-3.3). Additionally, there was evidence of effect modification by VDR expression; CaSR was associated with lethal progression among men with low tumor VDR expression (HR 3.2; 95% CI 1.4-7.3) but not in cases with high tumor VDR expression (HR 0.8; 95% CI 0.2-3.0). CONCLUSIONS: Tumor CaSR expression is associated with an increased risk of lethal prostate cancer, particularly in tumors with low VDR expression. These results support further investigating the mechanism linking CaSR with metastases.
CONTEXT: Prostate cancer metastases preferentially target bone, and the calcium-sensing receptor (CaSR) may play a role in promoting this metastatic progression. OBJECTIVE: We evaluated the association of prostate tumorCaSR expression with lethal prostate cancer. DESIGN: A validated CaSR immunohistochemistry assay was performed on tumor tissue microarrays. Vitamin D receptor (VDR) expression and phosphatase and tensin homolog tumor status were previously assessed in a subset of cases by immunohistochemistry. Cox proportional hazards models adjusting for age and body mass index at diagnosis, Gleason grade, and pathological tumor node metastasis stage were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of CaSR expression with lethal prostate cancer. SETTING: The investigation was conducted in the Health Professionals Follow-up Study and Physicians' Health Study. PARTICIPANTS: We studied 1241 incident prostate cancer cases diagnosed between 1983 and 2009. MAIN OUTCOME: Participants were followed up or cancer-specific mortality or development of metastatic disease. RESULTS: On average, men were followed up 13.6 years, during which there were 83 lethal events. High CaSR expression was associated with lethal prostate cancer independent of clinical and pathological variables (HR 2.0; 95% CI 1.2-3.3). Additionally, there was evidence of effect modification by VDR expression; CaSR was associated with lethal progression among men with low tumorVDR expression (HR 3.2; 95% CI 1.4-7.3) but not in cases with high tumorVDR expression (HR 0.8; 95% CI 0.2-3.0). CONCLUSIONS:TumorCaSR expression is associated with an increased risk of lethal prostate cancer, particularly in tumors with low VDR expression. These results support further investigating the mechanism linking CaSR with metastases.
Authors: Shozo Yano; R John Macleod; Naibedya Chattopadhyay; Jacob Tfelt-Hansen; Olga Kifor; Robert R Butters; Edward M Brown Journal: Bone Date: 2004-09 Impact factor: 4.398
Authors: V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak Journal: Cell Date: 1998-10-02 Impact factor: 41.582
Authors: Jennifer R Stark; Sven Perner; Meir J Stampfer; Jennifer A Sinnott; Stephen Finn; Anna S Eisenstein; Jing Ma; Michelangelo Fiorentino; Tobias Kurth; Massimo Loda; Edward L Giovannucci; Mark A Rubin; Lorelei A Mucci Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: J Michael Gaziano; Robert J Glynn; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Howard D Sesso; Julie E Buring Journal: JAMA Date: 2008-12-09 Impact factor: 56.272
Authors: Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway Journal: Nature Date: 2011-02-10 Impact factor: 49.962
Authors: Fatemeh Momen-Heravi; Yohei Masugi; Zhi Rong Qian; Reiko Nishihara; Li Liu; Stephanie A Smith-Warner; NaNa Keum; Lanjing Zhang; Nairi Tchrakian; Jonathan A Nowak; Wanshui Yang; Yanan Ma; Michaela Bowden; Annacarolina da Silva; Molin Wang; Charles S Fuchs; Jeffrey A Meyerhardt; Kimmie Ng; Kana Wu; Edward Giovannucci; Shuji Ogino; Xuehong Zhang Journal: Int J Cancer Date: 2017-09-20 Impact factor: 7.396
Authors: Irene Orlow; Yang Shi; Peter A Kanetsky; Nancy E Thomas; Li Luo; Sergio Corrales-Guerrero; Anne E Cust; Lidia Sacchetto; Roberto Zanetti; Stefano Rosso; Bruce K Armstrong; Terence Dwyer; Alison Venn; Richard P Gallagher; Stephen B Gruber; Loraine D Marrett; Hoda Anton-Culver; Klaus Busam; Colin B Begg; Marianne Berwick Journal: Pigment Cell Melanoma Res Date: 2017-11-05 Impact factor: 4.693
Authors: Wanshui Yang; Li Liu; Yohei Masugi; Edward Giovannucci; Shuji Ogino; Xuehong Zhang; Zhi Rong Qian; Reiko Nishihara; NaNa Keum; Kana Wu; Stephanie Smith-Warner; Yanan Ma; Jonathan A Nowak; Fatemeh Momen-Heravi; Libin Zhang; Michaela Bowden; Teppei Morikawa; Annacarolina da Silva; Molin Wang; Andrew T Chan; Charles S Fuchs; Jeffrey A Meyerhardt; Kimmie Ng Journal: Gut Date: 2017-07-04 Impact factor: 31.793